It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery. It is also used as a heparin substitute in heparin-induced thrombocytopenia (HIT) which may otherwise cause paradoxical thrombosis.<unk>  is used for thrombosis prophylaxis and treatment in heparin-induced thrombocytopenia patients. Although pre-treatment serological cross-reactivity with heparin-induced antibodies can occur in 5.2% of the patients it bears no systematic relationship with clinical cross-reactivity, 3.2% in the same study of 1478 patients with acute HIT Magnani & Gallus Thromb Haemost 2006;95:967-81 (ESRA). It is also approved for the treatment of DIC in Japan and although not approved for the following it has shown efficacy and safety in 406 case reports of paediatric use Bidlingmaier et al. Acta Haematologica 2006;115:237-247, pregnancy see Magnani HN. Thromb Res 2010;125:297-302 197 cases & 81 additional uses to protect cesarian section, patients in renal failure requiring intermittent Magnani HN. Thromb Res 2010;125:e171-e176 or continuous (CVVRT) Magnani HN & Wester JPJ. Open access Scientific Reports 2012;1/9:423-9 renal replacement therapy and in patients with hepatic disorders associated with cirrhosis such as portal vein thrombosis Fujiyama et al. BMC Gatsroenterol 2017;17:112-20 and the sinusoidal obstruction syndrome Kato et al. Pediatr Transplant 2017;e13099 and thrombotic micro-angiopathy Machida et al. Bone Marrow Transplant 2016;1-3 Doi:10.1038/bmt.2016.270 that occur after haemopoietic stem-cell transplantation in patients with haematogenous and solid malignancies. It has also been used in Kasabach-Merritt syndrome in 3 cases.
Danaparoid
Vosoritide
Oprelvekin
Prasugrel
Tirzepatide
Protokylol
Ganirelix
Cobicistat